What is the safety profile of bimekizumab and what are the most common adverse effects seen so far?
Featuring Mark Lebwohl, MD | Senior Clinical Advisor |
Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Related Media
Powered by Polaris TM